Expression of β-tubulin III and Bcl-2 and the clinical significance in non-small cell lung cancer

Chinese Journal of New Drugs

Volumn 18, Issue 9, 2009, Pages

  Gong, Jian ^a   Liu, Zhi Liang ^a   Ha, Min Wen ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

tubulin III; Bcl 2; Non small cell lung cancer; Paclitaxel; Resistance

Indexed keywords

BETA TUBULIN; PROTEIN BCL 2; TAXANE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION;

EID: 77954991793     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. RINALDI M, CAUCHI C, GRIDELLI C. First line chemotherapy in advanced or metastatic NSCLC [J]. Ann Onc, 2006, 17 (Suppl 5): S64-S67.
2. VERDIER PINARD P, WANG F, MARTELLO L, et al. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusingand mass spectrometry [J]. Biochemistry, 2003, 42(18): 5349-5357.
3. PASCAL S, MACKEY J, ISAAC S, et al. Class III beta-tubulin expression in turner cell predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel[J]. Mol Cancer Ther, 2005, 4(12): 2001-2007. (Pubitemid 43056983)
4. HUANG Y, IBRADO AM, REED JC, et al. Co-expression of several molecular mechanisms of multidurg resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells [J]. Leukemia, 1997, 11(2): 253-257.
5. KAWATANI M, IMOTO M. Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion[J]. Biol Chem, 2003, 278(22): 19732-19742.